48,830
edits
(→Invasive ductal carcinoma of the pancreas: fix ref) |
|||
Line 676: | Line 676: | ||
*Rare. | *Rare. | ||
*Presentation depends on subtype, e.g. for ''insulinoma'' the typical presentation is hypoglycemia. | *Presentation depends on subtype, e.g. for ''insulinoma'' the typical presentation is hypoglycemia. | ||
*May be part of a syndrome: | |||
**[[Muliple endocrine neoplasia I]]. | |||
====Classification==== | ====Classification==== | ||
Based on peptide produced: | Based on peptide produced in the pancreatic islets: | ||
#Glucagon from alpha cells (glucagonoma). | #Glucagon from alpha cells (glucagonoma). | ||
#Insulin from beta cells (insulinoma) - most common ~ 50% of islet cell tumours. | #Insulin from beta cells (insulinoma) - most common ~ 50% of islet cell tumours. | ||
#Somatostatin from D cells (somatostatinoma). | #Somatostatin from D cells (somatostatinoma). | ||
#Pancreatic polypeptide from PP cells. | #Pancreatic polypeptide from PP cells. | ||
Others: | |||
#Vasoactive intestinal peptide (VIPoma). | |||
#Gastrin (gastrinoma). | |||
#*Zollinger-Ellison syndrome - triad: pancreatic gastrinoma, gastric acid hypersecretion, marked peptic ulcers in the small bowel.<ref name="pmid13259432">{{cite journal |author=Zollinger RM, Ellison EH |title=Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas |journal=Ann. Surg. |volume=142 |issue=4 |pages=709–23; discussion, 724–8 |year=1955 |pmid=13259432|doi=10.1097/00000658-195510000-00015}}</ref> | |||
===Microscopic=== | ===Microscopic=== |
edits